J&J Settles Talc Suits for $5.5B as Amazon Scales Back AI Models

Johnson and Johnson announced a major settlement this week aimed at resolving the bulk of remaining lawsuits over its talc based products and their alleged links to ovarian cancer. The company said it would pay roughly 5.5 billion dollars to address about 76,000 claims now pending in federal court in New Jersey and various state courts. The agreement requires acceptance from 95 percent of eligible claimants before it takes effect and includes scheduled payments beginning with 3 billion dollars in 2027.

The deal comes after years of mixed trial outcomes and repeated attempts by the company to resolve the litigation through bankruptcy filings that courts ultimately rejected. Johnson and Johnson had already settled most claims involving asbestos contamination and mesothelioma. Company officials described the ovarian cancer cases as without merit yet chose resolution to limit further uncertainty. Erik Haas, the vice president of litigation, noted that the company believed it would prevail in most remaining trials but viewed the settlement as a way to refocus resources on its core pharmaceutical and medical device businesses.

Plaintiff attorneys involved in the negotiations expressed satisfaction with the outcome after a decade of litigation. Chris Seeger, who represents several thousand clients, helped shape the terms and viewed the agreement as a practical end to prolonged proceedings that had drained both sides. The structure ties additional payments to participation levels, giving the company some flexibility if fewer claimants opt in than projected.

The settlement highlights ongoing questions about how large corporations manage product liability risks over extended periods. Talc has been used in consumer products for generations, yet scientific debate over its safety profile continues even as regulators in some countries have restricted or banned certain applications. Johnson and Johnson maintains that its products have always been safe and that independent reviews support that position. Critics of the litigation argue that juries have sometimes been swayed by emotional presentations rather than consistent scientific evidence.

From a policy perspective the case illustrates the limits of the civil justice system in handling mass claims involving complex medical causation. Repeated bankruptcy maneuvers that failed suggest courts are reluctant to allow companies to shed liabilities through restructuring when the underlying products remain in commerce. At the same time, the scale of the payout shows how settlement pressure can mount even when a defendant wins most individual trials. Future regulatory approaches may focus more on pre market testing requirements and post market surveillance rather than relying primarily on after the fact lawsuits.

The agreement does not resolve every pending claim and leaves open the possibility that holdouts could pursue separate actions. Still, it represents the most comprehensive effort yet to draw a line under the dispute. For Johnson and Johnson the priority now shifts to execution of payments and demonstration that its remaining portfolio of medicines and devices can drive growth without the overhang of this litigation.